Massachusetts Medicaid and tirzepatide
Zepbound for weight loss: no. Not covered when used only for obesity or overweight. For the other accepted uses (heart disease, sleep apnea, MASH, or under 21 under EPSDT), Zepbound is no longer preferred and needs a trial of Wegovy first. Mounjaro for weight loss: no; for type 2 diabetes Massachusetts Medicaid must cover it. Read from Massachusetts Executive Office of Health and Human Services, MassHealth documents Nov 6, 2026.
In 2025 Massachusetts Medicaid paid for 269,389 tirzepatide prescriptions (Zepbound, Mounjaro), 68% of its GLP-1 prescriptions and 2nd of the 50 states and DC. It reimbursed $274.6 million before rebates, $1,019 a prescription against $1,032 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Zepbound | 208,115 | $212.9 million | $1,023 |
| Mounjaro | 61,274 | $61.7 million | $1,007 |
Massachusetts plans and prescribing rules
Massachusetts Group Insurance Commission (GIC). The GIC voted to end coverage of GLP-1s for obesity alone. From July 1, 2026, GIC plans cover them only for diabetes, or for members with a BMI of 27 or higher and an FDA-approved comorbid condition.
Tirzepatide in the states around Massachusetts
| State | Sell tirzepatide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Zepbound for weight loss |
|---|---|---|---|---|
| Massachusetts | 16 | $69/moWellmedr | 269,389 | Medicaid Zepbound: No |
| Connecticut | 17 | $69/moWellmedr | 53,677 | Medicaid Zepbound: No |
| New Hampshire | 17 | $69/moWellmedr | 9,302 | Medicaid Zepbound: No |
| New York | 17 | $69/moWellmedr | 218,875 | Medicaid Zepbound: No |
| Rhode Island | 17 | $69/moWellmedr | 12,587 | Medicaid Zepbound: Not confirmed (KFF) |
| Vermont | 17 | $69/moWellmedr | 2,783 | Medicaid Zepbound: No |



